It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Negative symptoms in schizophrenia strongly contribute to poor functional outcomes, however its pathogenesis is still unclear. Here, we found that histamine H1 receptor (H1R) expression in basal forebrain (BF) cholinergic neurons was decreased in patients with schizophrenia having negative symptoms. Deletion of H1R gene in cholinergic neurons in mice resulted in functional deficiency of cholinergic projections from the BF to the prefrontal cortex and in the formation of sensorimotor gating deficit, social impairment and anhedonia-like behavior. These behavioral deficits can be rescued by re-expressing H1R or by chemogenetic activation of cholinergic neurons in the BF. Direct chemogenetic inhibition of BF cholinergic neurons produced such behavioral deficits and also increased the susceptibility to hyperlocomotion. Our results suggest that the H1R deficiency in BF cholinergic neurons is critical for sensorimotor gating deficit, social impairments and anhedonia-like behavior. This finding may help to understand the genetic and biochemical bases of negative symptoms in schizophrenia.
Social impairment and anhedonia are common negative symptoms in patients with schizophrenia. Here, the authors show that the histamine H1 receptor in cholinergic neurons in the basal forebrain has a critical role in sensorimotor gating, social behaviour, and anhedonia-like behaviour in mice.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Wang, Lu 2 ; An Dadao 2 ; Jiang, Lei 2 ; Zheng Yanrong 2 ; Xu, Yixin 2 ; Wang, Yi 1
; Wang, Yujing 2 ; Zhang, Kuo 3 ; Wang, Xiaodong 2
; Zhang Xiangnan 2
; Bao Aimin 2 ; Zhou, Yudong 2
; Yang, Jingyu 3 ; Duan Shumin 2
; Swaab, Dick F 4 ; Hu, Weiwei 2
; Chen, Zhong 1
1 Zhejiang University, Institute of Pharmacology & Toxicology, NHC and CAMS Key Laboratory of Medical Neurobiology, College of Pharmaceutical Sciences, School of Basic Medical Sciences, Hangzhou, P.R. China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang Chinese Medical University, Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, College of Pharmaceutical Sciences, Hangzhou, P.R. China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924)
2 Zhejiang University, Institute of Pharmacology & Toxicology, NHC and CAMS Key Laboratory of Medical Neurobiology, College of Pharmaceutical Sciences, School of Basic Medical Sciences, Hangzhou, P.R. China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
3 Shenyang Pharmaceutical University, Department of Pharmacology, Shenyang, P.R. China (GRID:grid.412561.5) (ISNI:0000 0000 8645 4345)
4 Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263)




